Wyeth, ASKA, Takeda Report Changes In SELTOUCH’s Japanese Sales, Distribution

Wyeth (WKK), ASKA and Takeda have reported changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, SELTOUCH Pap 70, 140 (SELTOUCH).

WKK and ASKA signed an agreement in which the sales right for SELTOUCH is granted to ASKA. Additionally, ASKA and Takeda have also signed an agreement under which the sales and promotion of SELTOUCH are entrusted to Takeda.

Reportedly, under these agreements, Takeda will assume promotion of SELTOUCH from October 2009, while continuing the sales to wholesalers.

Meanwhile, since promotional activities of ASKA are limited in the orthopedic surgery area (in which SELTOUCH is mainly prescribed), it has decided to entrust promotion to Takeda, focusing on the physical distribution of SELTOUCH to Takeda.